Regeneron's fasinumab successful in mid-stage study in treatment-resistant …

Regeneron's fasinumab successful in mid-stage study in treatment-resistant …

At week 16, patients treated with fasinumab showed a statistically valid improvement in pain relief, the primary endpoint of the study, in addition to improvements in physical function. The results will be presented at an upcoming medical conference

(Visited 3 times, 1 visits today)
2
Like
Save

Comments

Write a comment